Form 4 for IMVT Immunovant, Inc.
Accepted 2026-06-26 19:45:00 ET · period of report 2026-06-26 · accession 0001764013-26-000073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-26 19:45 | 2026-06-26 | IMVT | Van Tuyl Christopher | CLO | M - OptEx | $15.20 | +17.8K | 198.4K | +10% | +$270.9K |
| DM | 2026-06-26 19:45 | 2026-06-26 | IMVT | Van Tuyl Christopher | CLO | S - Sale+OE | $38.31 | -17.8K | 180.6K | -9% | -$682.9K |
| D | 2026-06-26 19:45 | 2026-06-26 | IMVT | Van Tuyl Christopher | CLO | M - OptEx | $0.00 | -17.8K | 53.7K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-26 | M | A | 17,824 | $15.20 | 198,421 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-26 | S | D | 14,982 | $38.19 | 183,439 | D | — | — | (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 - $38.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 3 | Common | Common Stock | 2026-06-26 | S | D | 2,842 | $38.96 | 180,597 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 - $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 4 | Derivative | Stock Option (right to buy) | 2026-06-26 | M | D | 17,824 | $0.00 | 53,707 | D | $15.20 · — to 2035-04-01 | 17,824 Common Stock | (F3) Award of stock options to purchase Common Shares with a grant date of April 1, 2025. The shares underlying the option vest as to 25% on April 1, 2026, with the remainder vesting in 36 successive substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continued service to the Issuer as of such date. |